New strategies in personalized medicine for solid tumors: molecular markers and clinical trial designs

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Advances in tumor biology and molecular profiling technologies have ushered in a new era of personalized medicine in oncology.
• Academic institutions increasingly utilize molecular profiling for patient case discussions and treatment recommendations.
• Pharmaceutical clinical trials often require specific molecular markers for patient enrollment.

Purpose of the Study:

• To highlight the paradigm shift towards personalized medicine in oncology driven by molecular profiling.
• To discuss the integration of various profiling methods (genetic, RNA, protein, immune) in clinical research.
• To emphasize the ongoing evaluation of novel targeted agents and their potential patient benefit.

Main Methods:

• Broad molecular profiling of tumors.
• Analysis of genetic, RNA, protein, and immune parameters.
• Clinical evaluation of novel targeted agents with companion profiling.

Main Results:

• Personalized medicine tumor boards are routine in academic institutions.
• Numerous novel targeted agents are in clinical development with companion profiling.
• Genetic analyses are the current focus, with RNA, protein, and immune profiling emerging.

Conclusions:

• Molecular profiling is central to personalized oncology treatment strategies.
• Future patient selection and treatment approaches will likely incorporate diverse molecular and immune parameters.
• Translating tumor biology insights and novel agent development into tangible patient benefit remains a key objective.